Clinical Trial Update: Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating continuous or intermittent extension of adjuvant pyrotinib for invasive HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: RenJi Hospital | Conditions: Breast Cancer Invasive | Phase 3 | Status: RECRUITING